4Dotsika E,Karagouni E,Sundquist B,et al,Influence of Quillaja saponaria triterpenoid content on the immunomodulatory capacity of Epstein Barr virus ISCOMs[J].Scand J Immunol, 1997,45:261-265.
5Sessler W G, Jung G.Synthetic lipopepitides as nevl adjuvants [J].Res Immunol,1992,143 (5):548.
6O Haagan D T, Mackichan M L,Singh M.Recent development in adjuvants for vaccines agaist infectious diseases[J].Biom olecular engineering,2001,18(3):69-85.
7Barr I G ,Sjolander A,Cox J C.ISCOMs and other saponin based adjuvants[J]. Advanced Drug Delivery Reviews,1998, 32:247-271.
8Sessler W G,.Jung G..Synthetic lipopepitides as nvel adjuvants [J]. Red immunol engineering, 1992,143(5):548.
9Aucouturier J, Dupuis L,Ganne V. Adjuvants designed for veterinary and human vaccines[J]. Vaccine,2001,19(17-19): 2666-2672.
10Hioe CE,Qiu H ,Chend PD,et al.comparison of adjuvant formulation for cytotoxic T cell induction using synthetic peptides[J].Vaccine, 1996,14(2):412-418.
